Nanalysis Returns to Positive Quarterly EBITDA Despite Lower 2025 Revenue

Nanalysis Scientific ( (TSE:NSCI) ) just unveiled an update.

Nanalysis Scientific reported fourth-quarter 2025 revenue of $10.7 million, down 13% year-over-year, and full-year revenue of $40.1 million, a 12% decline, but returned to positive quarterly adjusted EBITDA of $1.2 million. Management said the company faced a difficult operating environment, including supply chain disruptions and a soft scientific instrumentation market, but has taken steps to improve leadership, service operations, and supply chain resilience, which they believe positions Nanalysis for more consistent execution and margin improvement.

Product sales and security services both experienced margin pressure in the fourth quarter, with product gross margin falling to 56% and service gross margin to 11% amid higher-cost labour and contract dynamics on a major security services agreement. The company remains in a normalized net loss position, but is working with key customers to establish more sustainable arrangements and is pursuing strategic initiatives to enhance profitability in both its scientific equipment and services businesses going forward.

The most recent analyst rating on (TSE:NSCI) stock is a Buy with a C$0.50 price target. To see the full list of analyst forecasts on Nanalysis Scientific stock, see the TSE:NSCI Stock Forecast page.

More about Nanalysis Scientific

Nanalysis Scientific Corp. is a Calgary-based company specializing in portable nuclear magnetic resonance (NMR) spectrometers and MRI technology for industrial and research applications. The company generates revenue from scientific product sales and security services, with a growing focus on its service operations and scientific equipment segment to diversify markets and strengthen its supply chain.

Average Trading Volume: 50,490

Technical Sentiment Signal: Sell

Current Market Cap: C$20.08M

For a thorough assessment of NSCI stock, go to TipRanks’ Stock Analysis page.